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Abstract: Parkinson’s disease (PD) is the most common form of movement disorder and 
affects approximately 4% of the population aged over 80 years old. Currently, PD cannot 
be prevented or cured, and no single diagnostic biomarkers are available. Notably, recent 
studies suggest that two familial PD-linked molecules, -synuclein and DJ-1, are present in 
cerebrospinal fluid (CSF) and that their levels may be altered during the progression of PD. 
In this regard, sensitive and accurate methods for evaluation of -synuclein and DJ-1 levels 
in the CSF and blood have been developed, and the results suggest that the levels of both 
molecules  are  significantly  decreased  in  the  CSF  in  patients  with  PD  compared  with  
age-matched  controls.  Furthermore,  specific  detection  and  quantification  of  neurotoxic 
oligometric forms of -synuclein in the blood using enzyme-linked immunosorbent assays 
might be expected as potential peripheral biomarkers for PD, although further validation is 
required. Currently, neither -synuclein nor DJ-1 is satisfactory as a single biomarker for 
PD, but combinatory evaluation of these biological fluid molecules with other biomarkers 
and imaging techniques may provide reliable information for diagnosis of PD.  
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1. Introduction  
Biological fluid biomarkers in blood samples, urine and cerebrospinal fluid (CSF) are measurable 
markers of underlying disease. For example, plasma prostate-specific antigen has been established as a 
biomarker for screening, early diagnosis, and tracking of tumor progression in prostate cancer [1]. 
Blood hemoglobin A1c is commonly used for diagnosis of diabetes mellitus and for predicting and 
monitoring  the  severity  of  cardiovascular  events  [2].  In  neurodegenerative  diseases  such  as 
Alzheimer’s disease (AD), alterations of amyloidogenic proteins, including -amyloid and tau, have 
been widely investigated. The levels of these molecules in the CSF are insufficient for them to be 
utilized as biomarkers, but the recent AD Neuroimaging Initiative study indicated that CSF -amyloid 
and tau protein analysis combined with neuroimaging techniques such as magnetic resonance imaging 
(MRI) and positron emission tomography (PET) may provide reliable information for early diagnosis 
and tracking of severity in AD [3]. Advance of neuroimaging methods, such as a high field MRI 
showing  increased  iron  content  in  the  substantia  nigra  [4,5],  [
123I]-meta-iodobenzylguanidine 
myocardial scintigraphy [6], and PET [7], could be also useful for the diagnosis of early stages of 
Parkinson’s disease (PD). However, these examinations are generally expensive and are not available 
in all hospitals. Thus, much expectation has been paid to the discovery of simple and convenient 
biomarkers specific for the pathogenesis of PD. 
PD  is  a  common  neurodegenerative  disease  that  presents  with  tremor,  rigidity  and  postural 
instability. PD is characterized pathologically by selective degeneration of the dopaminergic neurons of 
the  substantia  nigra  in  association  with  formation  of  Lewy  body  inclusions  and  Lewy  dystrophic 
neuritis [8]. Since the discovery of missense mutations (A53T and A30P) of -synuclein in familial 
cases  of  PD  (PARK1),  numerous  histological  studies  have  shown  that  -synuclein  is  a  major 
component in Lewy bodies [8]. Subsequently, several familial PD-linked mutations, including parkin 
(PARK2),  UCHL-1  (PARK5),  PINK1  (PARK6),  DJ-1  (PARK7),  LRRK2  (PARK8)  and  
ATP13A2 (PARK9), have been identified [9]. For -synuclein, gene triplication has been found in 
familial PD (PARK4) [9] and an E46K mutation was identified in a family with dementia with Lewy 
bodies (DLB) [10]. 
Given the common neuropathological features between familial and sporadic cases of PD, changes 
in familial PD-linked molecules are likely to be involved in the pathogenesis of sporadic PD. Thus, 
these  PD-linked  molecules  are  candidate  biomarkers  for  PD.  In  this  context,  several  studies  have 
compared  the  levels  of  CSF  and  blood  -synuclein  and  DJ-1  between  PD  patients  and  non-PD 
controls. Although the results are conflicting, it appears that -synuclein and DJ-1 in CSF, but not in 
blood, are significantly decreased in PD patients compared to non-PD controls [11,12]. Therefore, the 
purpose of this review is to summarize the studies on CSF and blood -synuclein and DJ-1 as possible 
biomarkers for PD.  
2. Evaluation of CSF and Blood -Synuclein as a Biomarker of PD 
Previous studies have shown that concentrations of CSF biomarkers for AD, such as -amyloid and 
tau, correspond well with brain alterations during disease progression [13]. In a similar context, several 
studies have evaluated CSF -synuclein levels in PD. Jakowec et al. performed immunoblot analysis, Int. J. Mol. Sci. 2010, 11                       
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but failed to detect the native form of -synuclein in the CSF of PD patients and non-PD controls [14]. 
Borghi et al. identified a 19 kDa monomeric -synuclein by immunoprecipitation and immunoblotting 
with different anti--synuclein antibodies, and concluded that the amount of CSF -synuclein did not 
vary significantly between PD and non-PD cases [15]. Ohrfelt et al. measured CSF -synuclein levels 
with enzyme-linked immunosorbent assays (ELISA) that allows for precise quantification (down to 
50 pg/mL) of -synuclein in CSF, but failed to see any significant differences among PD, DLB and 
their controls [16]. Thus, these studies suggested that -synuclein in CSF is not a useful biomarker of 
PD. In contrast, Mollenhauer et al. and Tokuda et al. performed ELISA to measure CSF -synuclein 
levels  and  found  significant  decreases  of  -synuclein  in  PD  patients  compared  with  non-PD  
controls  [17,18].  Interestingly,  Tokuda  et  al.  observed  a  strong  inverse  correlation  between  CSF  
-synuclein levels and disease severity evaluated by Hoenh-Yahr stage, and suggested that the CSF  
-synuclein levels may be a potential marker to aid clinical diagnosis of PD [18]. Thus, these studies 
have yielded conflicting results.  
Characterization of -synuclein in blood has also been performed by several groups, and again the 
results are conflicting. Lee et al. measured the blood -synuclein levels using a commercially available 
ELISA kit in 105 PD patients, 38 MSA patients, and 51 age-matched controls. The -synuclein level 
was significantly elevated in patients with PD and MSA compared with controls, and was higher in 
patients with PD compared to those with MSA [19]. In contrast, Li et al. performed semi-quantitative 
immunoblot analysis to measure the blood -synuclein levels using antibody 97/8, which is specific for 
the -synuclein C-terminal region, in 27 PD and 11 non-PD cases, and found significantly decreased 
-synuclein levels in the PD cases compared to the non-PD controls [20].  
Several factors may account for the conflicting results, including variations in detection, sensitivity 
and accuracy in each experimental system. It is also possible that the different antibodies used in 
different assays might detect different species of the proteins. As Li et al. explained, the advantage of 
the Western blotting method is that it can measure specific species of full-length -synuclein, while 
ELISA systems might detect truncated -synuclein in addition to the full-length protein, as well as 
oligomers  and  other  cross-reactive  molecules  [20].  In  addition,  blood  contamination  may  prevent 
accurate evaluation of the CSF -synuclein level, since Nakai et al. showed that more than 90% of 
peripheral  erythrocytes  expressed  -synuclein  [21]  and  it  has  been  shown  that  -synuclein  is 
abundantly  expressed  in  platelets  [22].  Thus,  CSF  or  plasma  -synuclein  levels  are  likely  to  be 
increased when blood contamination or possible platelet stimulation occurs during sample preparation. 
The problem of blood contamination was conquered by Hong et al. who studied CSF -synuclein 
levels  using  sensitive  and  quantitative  Luminex  bead-based  assays  in  large  numbers  of  subjects 
(117 PD patients, 132 healthy individuals, and 50 AD patients) [11]. To address the possibility of 
blood contamination, a hemoglobin ELISA was performed for all CSF samples  [11]. Notably, the 
CSF -synuclein and DJ-1 levels were substantially increased in all samples that were contaminated 
with blood (>200 ng/mL hemoglobin). Thus, this study elegantly demonstrated that CSF -synuclein 
levels are decreased in PD cases compared to non-PD controls and AD cases, although there was no 
correlation with the severity of the disease. 
Another important issue in evaluation of CSF -synuclein is that the protein is prone to aggregation. 
Oligomeric and protofibril forms may play a role in neurotoxicity, and these forms, rather than the Int. J. Mol. Sci. 2010, 11                       
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monomer,  may  be  appropriate  targets  for  evaluation  of  CSF  -synuclein  as  a  biomarker.  Thus,  
El-Agnaf et al. developed a novel ELISA that detects exclusively oligomeric “soluble aggregates” of 
-synuclein [23], and found that oligomeric forms of -synuclein were significantly elevated in serum 
samples from PD patients compared with non-PD controls. This was the first demonstration that the 
extent  of  aggregation  of  -synuclein  is  reflected  in  the  serum  of  PD  patients.  However,  since  
-synuclein aggregates are composed of heterogeneous populations, it is unclear whether pathogenic 
aggregates are recognized by the anti--synuclein antibody, and further studies are required to address 
this question. Furthermore, since it is well established that Ser129-phosphorylation of -synuclein is 
associated with aggregation of -synuclein and Lewy body formation [24], it is important to determine 
whether phospho--synuclein can be used as a peripheral biomarker. 
Finally, emerging evidence suggests a role of secretion and possible propagation of -synuclein in 
the pathogenesis of PD [25]. The occurrence of Lewy pathology in neurons grafted into the brains of 
PD patients [26,27] suggests that -synuclein pathology can spread from host tissues to the grafts. The 
mechanism  underlying  this  propagation  is  still  unclear.  If  such  a  prion-like  transmissible  form  of  
-synuclein is indeed isolated in CSF, it may then be an ideal biomarker that is directly correlated with 
disease progression. Thus, future studies of CSF -synuclein may provide critical insights into the 
mechanism of pathological progression in PD and other proteinopathies.  
3. Evaluation of CSF and Blood DJ-1 as a Biomarker of PD 
DJ-1 was first identified by Nagakubo et al. as a novel oncogene that works in association with ras 
in cellular transformation [28]. It has subsequently been shown that DJ-1 is a multifunctional protein 
that is involved in various cellular processes, including response to oxidative stress, RNA binding, 
androgen-receptor signaling, spermatogenesis, and fertilization [29]. DJ-1 is secreted into the serum of 
patients with breast cancer, melanoma, familial amyloidotic polyneuropathy, and stroke [29]. Since the 
discovery of the linkage of gene mutations of DJ-1 to autosomal recessive familial PD (PARK7), much 
attention  has  been  paid  to  the  role  of  this  molecule  in  the  pathogenesis  of  PD  and  related 
neurodegenerative diseases [30]. Further investigation has shown that DJ-1 may play a protective role 
in oxidative stress during neurodegeneration [31].  
Choi et al. reported that the total level of DJ-1 measured by semi-quantitative immunoblot analysis 
is  significantly  increased  in  PD  and  AD  brains  [32].  Consistent  with  this,  we  observed  that  both 
monomer  and  aggregates  of  DJ-1  were  abundantly  present  in  the  CSF,  and  our  semi-quantitative 
immunoblot analysis revealed that CSF-1 DJ-1 monomer levels were significantly increased in PD 
compared to those in non-PD controls [33]. We also found that plasma DJ-1 levels were increased in 
PD cases compared to non-PD controls [34]. Thus, our results raise the possibility that CSF or serum 
DJ-1 could be used as a possible biomarker for PD. 
Our  findings  stimulated  investigation  of  CSF  and  blood  DJ-1  in  the  PD  field,  but  the  results 
obtained by other groups were variable and mostly contradictory to our data. Maita et al. examined  
DJ-1  levels  using  a  DJ-1  ELISA  kit  in  PD  cases  and  age-matched  controls,  but  did  not  find  a 
significant difference in the levels of secreted DJ-1 between these groups or correlations of DJ-1 levels 
with age and clinical severity [35]. Hong et al. conducted a careful measurement of CSF DJ-1, as 
described above for CSF -synuclein [11], with measurement of CSF DJ-1 levels using quantitative Int. J. Mol. Sci. 2010, 11                       
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Western blotting, in-gel digestion and mass spectrometry, size-exclusion chromatography, and a newly 
developed and highly sensitive bead-based Luminex assay [11]. Hemoglobin levels in the CSF samples 
were measured to check for the effect of blood contamination [11]. The results showed that CSF DJ-1 
and -synuclein levels were dependent on age and influenced by the extent of blood contamination in 
the CSF. Both DJ-1 and -synuclein levels were decreased in PD cases compared to non-PD controls 
and  AD  cases  after  elimination  of  the  effect  of  blood  contamination.  However,  there  was  no 
association  between  DJ-1  or  -synuclein  and  the  severity  of  PD  [11].  These  findings  led  to  the 
conclusion that total DJ-1 and -synuclein in human CSF are helpful diagnostic markers for PD, if 
variables such as blood contamination and age are taken into consideration. This work provides a 
reliable evaluation of CSF -synuclein and DJ-1 levels as biomarkers for PD. Subsequently, the same 
group  showed  that  plasma  DJ-1  or  -synuclein  levels  did  not  differ  in  PD  cases  compared  to  
age-matched controls and AD cases, and concluded that, unlike in the CSF, total DJ-1 or -synuclein 
in plasma alone is not useful as a biomarker for diagnosis, progression or severity of PD [12]. 
Finally,  it  is  worth  noting  that  Ooe  et  al.  developed  specific  antibodies  that  recognize  
C106-oxidized DJ-1 [36]. Examination of the oxidized DJ-1 levels could be more meaningful because 
abnormal  oxidized  DJ-1  has  been  specifically  increased  in  patients  with  PD  and  AD  [32,37]  and 
measurement of oxidized DJ-1 in the CSF or blood using these specific DJ-1 antibodies with Western 
blot and ELISA system could be useful. 
4. Other Potential Blood Biomarkers for PD 
At this stage, neither -synuclein nor DJ-1 alone appears to be satisfactory as a single biological 
fluid biomarker for PD. However, combinatory analysis of these molecules with other data might give 
useful  information.  Indeed,  previous  works  have  investigated  various  molecules  related  to  the 
pathogenesis of PD. 
First, oxidative stress and mitochondrial respiratory failure are implicated in loss of dopaminergic 
neurons in PD. Alam et al. showed a selective increase in 8-hydroxydeoxyguanosine (8-OHdG), a 
product of oxidized DNA or RNA, in the substance nigra in PD [38]. Kikuchi et al. showed increased 
levels  of  8-OHdG  in  the  serum  and  CSF  in  patients  with  PD  and  multiple  system  atrophy,  and 
suggested that systemic DNA/RNA oxidation is common in neurodegenerative diseases [39]. More 
recently, Sato and Hattori used an ELISA to show that urinary levels of 8-OHdG were increased in PD 
patients, and that mean urinary 8-OHdG levels increased with disease progression, which suggests that 
urinary 8-OHdG is a potential biomarker for progression of PD [40].  
Second, neuroinflammatory processes are well known to be associated with the pathogenesis of 
neurodegenerative  diseases,  including  PD  [41].  Activated  microglial  cells  are  found  within  the 
substantia nigra in autopsied PD patients, and increased levels of proinflammatory cytokines such as 
tumor necrosis factor  (TNF-), interleukin 6 (IL-6) and interleukin 1β (IL-1β) are also found in the 
substantia nigra in PD [42]. Inflammatory cytokines in biological fluids (CSF or serum) obtained from 
PD patients have been studied, since the levels of these molecules may reflect glial activation and 
inflammation in the brain [42]. Changes in the levels of proinflammatory molecules such as TNF-, 
IL-6  and  IL-1β,  which  may  be  derived  from  activated  microglia,  have  been  found  in  the  CSF  
of PD patients. Int. J. Mol. Sci. 2010, 11                       
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Third, the neurodegenerative process of PD is associated with altered expression of growth factors. 
Godau  et  al.  recently  showed  that  the  levels  of  serum  insulin-like  growth  factor  (IGF-1)  were 
significantly higher in treated PD patients than in controls [43]. Interestingly, higher serum IGF-1 
levels were correlated with shorter disease duration, and this led to the conclusion that increased IGF-1 
might  be  a  serum  marker  for  early  PD  and  potentially  for  subclinical  dopaminergic  dysfunction. 
However, the clinical value of this assay for diagnosis of PD is uncertain. 
5. Conclusions 
A number of recent studies have investigated -synuclein and DJ-1in CSF and blood as potential 
biomarkers for PD. Among the conflicting results, a most sophisticated work evaluating the possibility 
of blood contamination suggests that both  -synuclein and DJ-1 in CSF may be decreased in PD 
compared  to  non-PD  controls.  Nonetheless,  no  correlation  with  the  disease  severity  has  been 
confirmed. Thus, these results indicate that neither -synuclein nor DJ-1 is satisfactory as a single 
biological fluid biomarker for PD. In this situation, combinatory analysis of CSF -synuclein and/or 
DJ-1 with other PD biomarkers, such as oxidative stress-related molecules, pro-inflammatory factors 
and  some  growth  factors,  might  be  effective.  Alternatively, developing methods  to  detect  specific 
molecules underlying PD pathogenesis, such as oligomer, protofibrils and putative transmissible form 
of -synuclein taken from blood and CSF combined with genetic screenings of PD linked genes and 
imaging techniques would increase the possibility of detecting disease. 
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